Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
28 02 2023
28 02 2023
Historique:
received:
12
10
2022
accepted:
07
02
2023
entrez:
28
2
2023
pubmed:
1
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
We examined the effectiveness of maternal vaccination against SARS-CoV-2 infection in 30,311 infants born at Kaiser Permanente Northern California from December 15, 2020, to May 31, 2022. Using Cox regression, the effectiveness of ≥2 doses of COVID-19 vaccine received during pregnancy was 84% (95% confidence interval [CI]: 66, 93), 62% (CI: 39, 77) and 56% (CI: 34,71) during months 0-2, 0-4 and 0- 6 of a child's life, respectively, in the Delta variant period. In the Omicron variant period, the effectiveness of maternal vaccination in these three age intervals was 21% (CI: -21,48), 14% (CI: -9,32) and 13% (CI: -3,26), respectively. Over the entire study period, the incidence of hospitalization for COVID-19 was lower during the first 6 months of life among infants of vaccinated mothers compared with infants of unvaccinated mothers (21/100,000 person-years vs. 100/100,000 person-years). Maternal vaccination was protective, but protection was lower during Omicron than during Delta. Protection during both periods decreased as infants aged.
Identifiants
pubmed: 36854660
doi: 10.1038/s41467-023-36547-4
pii: 10.1038/s41467-023-36547-4
pmc: PMC9974935
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
894Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI168373
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023. The Author(s).
Références
Pediatrics. 2017 May;139(5):
pubmed: 28557752
N Engl J Med. 2022 Jul 21;387(3):227-236
pubmed: 35767475
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
N Engl J Med. 2022 Jul 14;387(2):187-189
pubmed: 35731916
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263
pubmed: 35176007
Pediatr Infect Dis J. 2022 Mar 1;41(3):e81-e86
pubmed: 34955519
Vaccine. 2013 Apr 19;31(17):2165-8
pubmed: 23499601
J Pediatr. 2022 Oct 15;:
pubmed: 36252864
JAMA. 2022 Mar 15;327(11):1087-1089
pubmed: 35129576
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1081-1088
pubmed: 32790664
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Vaccine. 2013 Jun 26;31(30):3104-9
pubmed: 23624093
JAMA Netw Open. 2022 Sep 1;5(9):e2233273
pubmed: 36156146
N Engl J Med. 2021 Jun 17;384(24):2273-2282
pubmed: 33882218
MMWR Morb Mortal Wkly Rep. 2021 Jun 18;70(24):895-899
pubmed: 34138834
Vaccine. 2017 Oct 13;35(43):5850-5857
pubmed: 28935471
Vaccine. 2022 Jan 28;40(4):656-665
pubmed: 35000794
MMWR Morb Mortal Wkly Rep. 2022 Jan 07;71(1):26-30
pubmed: 34990445
Vaccine. 2017 Dec 19;35(52):7297-7301
pubmed: 29146382
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
PLoS One. 2020 Feb 26;15(2):e0229279
pubmed: 32101582
JAMA. 2021 Oct 26;326(16):1629-1631
pubmed: 34495304
JAMA Netw Open. 2022 Sep 1;5(9):e2232760
pubmed: 36136332
Am J Obstet Gynecol. 2022 Feb;226(2):236.e1-236.e14
pubmed: 34389291
Perm J. 2016 Fall;20(4):15-225
pubmed: 27548806
Pediatr Infect Dis J. 2021 Apr 1;40(4):e137-e145
pubmed: 33538539
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):429-436
pubmed: 35298458
N Engl J Med. 2022 Jul 14;387(2):109-119
pubmed: 35731908
JAMA Intern Med. 2022 Aug 1;182(8):825-831
pubmed: 35648413
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Am J Epidemiol. 2020 Nov 2;189(11):1379-1388
pubmed: 32735018
MMWR Morb Mortal Wkly Rep. 2022 Mar 04;71(9):352-358
pubmed: 35239634
N Engl J Med. 2021 Oct 7;385(15):1355-1371
pubmed: 34496194
J Urban Health. 2006 Nov;83(6):1041-62
pubmed: 17031568